LSE-AIM$MXCT
Maxcyte Inc · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
Maxcyte's fourth quarter and full year results were announced, showing revenue increase in Q4 and FY 2022, and provided initial 2023 revenue guidance.
MaxCyte reported a 22% increase in total revenue for the fourth quarter of 2022, reaching $12.4 million. Core business revenues grew by 4%, driven by cell therapy and drug discovery customer growth. The company's SPL program-related revenue was $1.9 million. MaxCyte provided initial 2023 revenue guidance, expecting total revenue growth of 21% to 26% over 2022.
- Total revenue increased by 22% to $12.4 million in Q4 2022 compared to Q4 2021.
- Core business revenues grew by 4% in Q4 2022, with cell therapy and drug discovery revenues increasing by 4% and 5%, respectively.
- Ended the year with 18 SPL partnerships, with the addition of partnerships with Intima Bioscience, LG Chem, and Curamys in 2022.
- Gross profit for the fourth quarter of 2022 was $10.9 million (88% gross margin), compared to $8.9 million (88% gross margin) in the fourth quarter of 2021.
Headline financials
Revenue & EPS history
Maxcyte · Revenue · Quarterly
$12.4M
Revenue by segment
Maxcyte · $1.85M total across 1 segment · Q4 2022
- Program-Related$1.85M—100.0%
Forward guidance
MaxCyte anticipates total revenue growth of 21% to 26% over 2022, including core business revenue growth of 20% to 25% and SPL program-related revenue of approximately $6 million for the full year 2023.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2022
+291.3%
Avg return
Earnings day
-2.8%
Avg return
5 days after
+220.5%
Avg return
30 days after
42%
10 / 24 earnings
Positive
+7042.3%
Q1 2025
Best reaction
-29.9%
Q2 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +24.1% | +29.0% | — | |
| Q3 2025 | -12.0% | -7.2% | -12.0% | |
| Q2 2025 | -29.9% | -37.7% | -30.9% | |
| Q1 2025 | +7042.3% | -19.7% | -21.5% | |
| Q4 2024 | -8.4% | -6.1% | +5251.6% | |
| Q3 2024 | +0.5% | -7.3% | -6.7% | |
| Q2 2024 | +2.5% | -3.7% | -8.8% | |
| Q1 2024 | +0.5% | +21.2% | +23.5% | |
| Q4 2023 | +0.3% | +8.6% | +4.0% | |
| Q3 2023 | -1.5% | +2.4% | +42.6% | |
| Q2 2023 | -2.7% | -14.3% | -17.4% | |
| Q1 2023 | -0.6% | -19.2% | -2.8% | |
| Q4 2022 | +2.7% | +2.4% | +30.8% | |
| Q3 2022 | -9.4% | +3.0% | -19.9% | |
| Q2 2022 | +3.6% | +4.9% | +16.4% | |
| Q1 2022 | -4.3% | -13.0% | -12.9% | |
| Q1 2021 | -4.3% | -13.0% | -12.9% | |
| Q4 2021 | +3.4% | +6.7% | -23.7% | |
| Q4 2019 | +3.4% | +6.7% | -23.7% | |
| Q3 2020 | -7.7% | +3.8% | -9.7% | |
| Q3 2021 | -7.7% | +3.8% | -9.7% | |
| Q4 2020 | -4.1% | -6.2% | -26.3% | |
| Q2 2021 | -0.3% | -6.5% | -29.4% | |
| Q2 2020 | -0.3% | -6.5% | -29.4% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro